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Abstract 
The dopaminergic system plays a key role in motor function and motor abnormalities have 
been shown to be a specific feature of psychosis. Due to their dopaminergic action, 
antipsychotic drugs may be expected to modulate motor function, but the precise effects of 
these drugs on motor function remain unclear. We carried out a within-subject, double-blind, 
randomized study of the effects of aripiprazole, haloperidol and placebo on motor function in 
20 healthy men. For each condition, motor performance on an auditory-paced task was 
investigated. We entered maps of neural activation into a random effects general linear 
regression model to investigate motor function main effects. Whole-brain imaging revealed a 
significant treatment effect in a distributed network encompassing posterior 
orbitofrontal/anterior insula cortices, the inferior temporal, and postcentral gyri. Post-hoc 
comparison of treatments showed neural activation after aripiprazole did not differ significantly 
from placebo in either voxel-wise or region of interest analyses, with the results above driven 
primarily by haloperidol. We also observed a simple main effect of haloperidol compared with 
placebo, with increased task-related recruitment of posterior cingulate and precentral gyri. 
Furthermore, region of interest analyses revealed greater activation following haloperidol 
compared with placebo in the precentral and post-central gyri, and the putamen. These 
diverse modifications in cortical motor activation may relate to the different pharmacological 
profiles of haloperidol and aripiprazole, although the specific mechanisms underlying these 
differences remain unclear. Evaluating healthy individuals can allow investigation of the effects 
of different antipsychotics on cortical activation, independently of either disease-related 
pathology or previous treatment.  
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1. Introduction  
Antipsychotic medications, the pharmacological treatment of choice for schizophrenia, can 
alter motor function, leading to akathisia and extra-pyramidal motor side effects (EPS). 
However, the ability to induce motor side effects varies across different antipsychotics, 
although all of them target the dopaminergic system, which plays a fundamental role in 
regulating motor function. For example, haloperidol, a first generation antipsychotic (FGA), 
has been associated with EPS and alterations of motor neural activation in patients with 
schizophrenia, whilst second generation antipsychotics (SGA), such as olanzapine or 
quetiapine, are less likely to induce EPS. However, newer antipsychotics, such as aripiprazole 
(also termed a third generation antipsychotic), are also known to induce akathisia (inner 
restlessness, with outwardly observed rocking, fidgeting, and restlessness), although they 
have different effects on the dopaminergic system. To understand the effects of antipsychotics 
on motor function, it is therefore important to investigate what, if any, effect antipsychotic 
medications have on motor neural mechanisms without the confounding influence of disease 
pathophysiology.  
This is particularly important because motor function deficits, particularly in processing speed 
and psychomotor activity, are well documented in schizophrenia and other psychotic 
disorders, even in antipsychotic-naïve individuals (Liddle, 1987; Dazzan et al., 2004; 
Dickinson et al., 2007; Morrens et al., 2007; Dazzan et al., 2008). Motor function is modulated 
by dopaminergic signalling, particularly within the nigrostriatal system. Alterations within this 
system likely underlie the motor dysfunction observed in these patients. It is therefore essential 
to clarify the specific effects of different antipsychotic medications on motor function and its 
associated brain activation, independently from any underlying pathophysiological process.  
First generation antipsychotics (FGAs, such as haloperidol) have selective high affinity for, 
and antagonistic action at, dopamine D2 receptors, but lower affinity for other receptors, such 
as serotonin (5-HT) receptors (Meltzer et al., 1989). Conversely, second generation 
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antipsychotics (SGAs, such as risperidone) have broader affinities, showing antagonism at 
both D2 and 5HT receptors. Aripiprazole has often been referred to as a third generation 
antipsychotic due to differences in its affinities for, and action at, dopamine and 5-HT 
receptors. Importantly, aripiprazole is a partial D2 receptor agonist, rather than a full antagonist 
(blocker) of dopamine receptors. Partial agonists have both agonist and antagonist actions, 
depending on the presence of competing full agonists. Therefore, when there are excessive 
amounts of an endogenous ligand (i.e., in this case dopamine) they act to reduce 
overstimulation of a receptor. In addition to partial D2 agonism, aripiprazole is a partial agonist 
of 5-HT1A receptors (Jordan et al., 2002). Similarly to haloperidol, but in contrast to other SGA, 
aripiprazole also has lower affinity for the 5-HT2A than for the D2 receptor.  
The effects of antipsychotics on the brain have been investigated using behavioural and 
neuroimaging paradigms. Specifically, functional imaging paradigms have been used with 
simple activation tasks to investigate neural activation underlying motor function in both 
patients and healthy individuals. These tasks include finger-tapping, which reliably activates a 
motor loop of cortico-striatal-thalamo-cortical regions (Alexander et al., 1990).  
a) Antipsychotic effects on motor performance and associated neural function in patients with 
schizophrenia 
FGA and SGA may affect motor ability differently, given the differing modes of action of these 
different classes of medication. Behavioural studies have suggested that whilst FGA seem to 
have little effect on motor performance, SGA have been associated with improvement in motor 
ability in patients with schizophrenia (Woodward et al., 2005). Furthermore, switching from 
FGA to SGA may actually be associated with improved motor function (Ahn et al., 2009; 
Cuesta et al., 2009; Keefe et al., 2007; Cuesta et al., 2001), thus supporting arguments for 
superior benefit in cognitive function with SGA than FGA.  
Studies investigating the effects of antipsychotics on motor activation in schizophrenia report 
mixed findings. Muller and colleagues (2002a, b) compared neural activation during a finger-
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tapping task in patients with schizophrenia (10 treated with haloperidol, 10 with olanzapine, 
10 untreated) and healthy controls. Haloperidol treatment was associated with lower basal 
ganglia activation in patients than in healthy controls, whilst olanzapine was associated with 
lower motor cortex activation in patients than in healthy controls during the task (Muller et al., 
2002a,b). However, decreased cortical activation has been reported in association with FGA 
but not SGA treatment elsewhere (Braus et al., 1999). It is possible that SGA treatment leads 
to normalisation of motor activation in patients. For example, a longitudinal study of functional 
connectivity reported that patients showed greater connectivity than healthy controls at 
baseline, but this normalised with three weeks olanzapine treatment, such that patients 
became more similar to healthy controls (Stephan et al., 2001). This was further supported by 
another study on the effects of olanzapine on motor activation in patients (Bertolino et al., 
2004). Here, Bertolino and colleagues (2004) found that baseline hypoactivation in patients 
was altered, such that motor activation came to resemble that in healthy controls after eight 
weeks of olanzapine treatment.  
b) Antipsychotic effects on motor performance and associated neural activation in healthy 
individuals 
Interpretation of studies in patients is complicated by the presence of altered activation 
patterns that may be associated with disease pathophysiology. Therefore, studies have 
investigated the effect of antipsychotics on motor performance in healthy individuals, to 
evaluate their effects on motor function independently of underlying pathophysiology or 
symptom profiles. While most reported no effect of haloperidol on motor performance (Liem-
Moolenaar et al., 2010; Wezenberg et al., 2007; Lynch et al., 1997; Honey et al., 2003), one 
did report psychomotor impairments following a single dose of either haloperidol or 
olanzapine, with impairments induced by haloperidol lasting longer (Beuzen et al., 1999). 
Impaired performance on motor tasks (including increased reaction times/impaired speed of 
response) has been more often seen in healthy controls following administration of olanzapine 
than after haloperidol (Beuzen et al., 1999; Wezenberg et al. ,2007; de Bruijn et al., 2006; 
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Morrens et al., 2007). However, to date only one study investigated the effect of aripiprazole 
on motor performance in 20 healthy controls and did not find any effect (Liu et al. 2009), 
possibly because of its novel pharmacological profile.  
To our knowledge, only one study has investigated neural activation during a motor task after 
haloperidol in healthy controls (Tost et al., 2006). This study found decreased activation in 
several regions, lateralised to the non-dominant hemisphere. These included anterior 
cingulate and parietal regions, such as supplementary motor area, primary somatomotor 
cortex, premotor cortex, and also putamen, thalamus and cerebellum. In contrast, no study 
has evaluated neural activation during motor function following aripiprazole, either in patients 
or healthy controls. 
It therefore remains unclear whether and how different antipsychotics (D2 antagonists or 
partial agonists) affect simple motor function and its related neural activation. We explored for 
the first time the differential effects of a single dose of two different antipsychotics on motor 
function in healthy individuals using fMRI with a longitudinal, repeated measures design.  
We investigated motor function using a joystick task after administration of haloperidol (a D2 
antagonist) and aripiprazole (a D2 partial agonist) to the same healthy individuals. Based on 
previous studies, we predicted that haloperidol, but not aripiprazole, would reduce activation 
of cortical motor regions, including anterior cingulate, supplementary motor and premotor 
areas, and subcortical regions, including putamen and thalamus, compared with placebo. 
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2. Materials and methods 
2.1 Participants  
Twenty healthy, right-handed, English speaking, Caucasian male university students, 
participated in this study. They were aged 18 to 33 years (mean 23.0 years, SD 4.5), with 
mean IQ of 118.3 (SD 6.1) measured using the National Adult Reading Test (NART) (Nelson 
1982). Their body mass index was within the normal range (mean 23.6, SD 3.7) and all were 
non-smokers, with no recent or current drug use (illicit or prescribed). They had no previous 
exposure to psychotropic medications and did not have a personal or family history of 
psychiatric illness. 
This study was approved by the local Human Research Ethics Committee, and conducted in 
compliance with the Declaration of Helsinki. Written informed consent was obtained from all 
participants after the nature of the experimental procedures was explained to them. 
2.2 Procedures 
2.2.1 Antipsychotic administration 
Subjects received a single dose of haloperidol (3mg), aripiprazole (10mg), and placebo, 
administered in identical capsules across three visits, in a fully counterbalanced, randomized 
within-subject, double-blind crossover design. A minimum of 14 days’ drug washout was 
ensured between visits, and no alcohol or medications were used for 24 hours, or caffeine 
for 6 hours, prior to scanning. Time of administration before scanning and dose of 
antipsychotic ensured comparable levels of striatal D2 receptor occupancy for the two 
compounds to within the ‘window of therapeutic range’ (65-80%) during the scan (Kapur et 
al. 2000). A 16 ml blood sample was collected immediately before MRI scanning to assess 
antipsychotic plasma levels. The mean plasma level of haloperidol was 1 µg/L (SD 0.6; 
range 0.5 – 2.5 µg/L), and of aripiprazole was 42 µg/L (SD 11; range 23 – 55 µg/L). 
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Three hours after drug administration, clinical motor effects were measured using the Barnes 
Akathisia scale (Barnes, 1989), the Simpson-Angus scale (Simpson & Angus, 1970), and the 
Abnormal Involuntary Movement Scale (Guy, 1976). Both haloperidol and aripiprazole induced 
more extra-pyramidal side effects than placebo (χ2 = 7.3, p < 0.05). There were no significant 
differences across interventions in tardive dyskinesia (χ2 = 2.0, n.s.) or akathisia (no 
participants reported any symptoms). There were also no differences in systolic (F(2,32) = 
2.16, n.s.) or diastolic (F(2,32) = 0.15, n.s.) blood pressure. 
2.2.2 Motor task 
Participants completed a battery of cognitive tests after administration of each intervention. 
They completed an auditory-paced motor task in which they were presented with a tone 
through headphones. During an experimental block, the word ‘move’ was visually presented 
indicating that participants should move a joystick with their right hand when they heard a 
tone. During a control block, the word ‘rest’ was presented indicating that no movement was 
required even if tones were heard. For each intervention, participants completed five control 
and five experimental blocks, each lasting 17.5 seconds. During experimental blocks, targets 
were presented every 1.5 – 3.5 seconds, jittered to prevent automated rhythmic responses 
and with a total of 7 targets per block. Jittered tones were presented during the control blocks, 
although no response was required. The whole task lasted 3 minutes and 15 seconds, with 
rest and experimental blocks separated by a 2 second interval. 
2.2.3 BOLD acquisition   
Echo planar images (EPI) depicting blood oxygen level dependent (BOLD) contrast were 
obtained in a General Electric Signa HDX 1.5 Tesla scanner at the Centre for Neuroimaging 
Sciences, Institute of Psychiatry. Thirty-eight ascending, interleaved axial slices (3mm thick, 
0.3mm inter-slice gap) were acquired parallel to the intercommissural (AC-PC) plane during 
each session, with a repetition time of 2.5 seconds and an echo time of 40 seconds. BOLD 
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images provided neural correlates of the task. In addition, a high spatial resolution EPI image 
was also acquired for co-registration and normalisation of functional images. 
2.2.4 Data analysis 
2.2.4.1 Missing data 
Not all participants were included in all analyses. The reasons for missing data included 
image acquisition fault (n=1) and side effects after either haloperidol or aripiprazole resulting 
in missing functional motor task data after taking the antipsychotic (haloperidol, n=1; 
aripiprazole, n=3). As a result, the analysis of differences (for each intervention) in 
performance and activation during the motor task was based on n = 18 subjects for 
haloperidol versus placebo, n = 15 for haloperidol versus aripiprazole, and n = 17 for 
aripiprazole versus placebo.  
2.2.4.2 Behavioural analysis 
Behavioural data were analysed in the Statistical Package for Social Sciences, Version 15.0 
(SPSS Inc.). Number correct (NC) and reaction time to correct response (RTC) were 
recorded. Depending on whether data met the assumption of normality, T tests or chi-square 
tests were run to compare behavioural scores for haloperidol versus placebo, haloperidol 
versus aripiprazole, and aripiprazole versus placebo. Our results showed that neither 
antipsychotic intervention altered the behavioural performance on the task compared with 
placebo or one another, as measured by number correct (NC) or reaction time to correct 
(RTC) (Table 1). As such, we present only the data for neural activation in our results below.  
[Table 1] 
2.2.4.3 BOLD image analysis 
All image analysis procedures were carried out using the Statistical Parametric Mapping 
suite (SPM, version 5-1782) developed by the Functional Imaging Laboratory, University 
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College London (www.fil.ion.ucl.ac.uk/spm). Images were reoriented to the AC-PC line 
(using http://imaging.mrc-cbu.cam.ac.uk/imaging/FindingCommissures for guidance) prior to 
realignment. A 6-parameter rigid body spatial transformation was used for within-subject 
registration to realign images to each other and then to the mean time series image, and 
movement parameters were extracted. A good quality EPI image (selected visually from one 
of three sessions) was normalised using 16 nonlinear iterations and 7x9x7 basis functions to 
the standard EPI template in SPM5 (conforms to the ICBM NIH p-20 project; (Evans et al., 
1993)). This generated normalisation parameters for optimal matching between the standard 
template space, the high resolution image, and subsequently the EPI time series. Finally, 
images were smoothed with a 10mm Gaussian kernel filter.  
For the first level analysis, subject-specific fMRI data identified activation patterns for each 
subject representing areas activated by the simple motor task. These maps, containing 
activation exclusive to motor function, were entered into a random effects general linear 
regression model to explore group effects. These contrasts were taken forward to a random 
effects group-level model. Specifically, a repeated-measures ANOVA was implemented as a 
flexible factorial. In addition, we included three nuisance regressors encoding dosing order 
(i.e., dose 1, 2, and 3) in the model to control for potential order effects. Supra-threshold 
cluster-level statistics were then accepted at p < 0.05, corrected for multiple comparisons 
across the whole brain.  
Whilst a voxel-wise approach allowed us to explore regions affected by the antipsychotic 
medications across the whole brain, we also used a region of interest approach to 
specifically investigate brain regions known to be associated with motor performance. Small 
volume corrections (SVC) were conducted using independent, a priori, anatomically defined 
regions, identified in the anatomical automatic labelling (AAL) toolbox extension of SPM5 
(Tzourio-Mazoyer et al., 2002). We selected nine a priori regions, with our choice informed 
by a meta-analysis (Witt et al., 2008). These included precentral gyrus, postcentral gyrus, 
supplementary motor region, inferior parietal, inferior frontal (pars opercularis), putamen, 
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caudate, thalamus, and cerebellum. SVC were applied to each contrast bilaterally, with 
voxel-level statistics accepted at p < 0.05 corrected for family-wise error (FWE). All MNI co-
ordinates were labelled using a combination of the Talairach and Tornaux atlas (Talairach & 
Tournoux, 1988), the fslview MNI structural atlas (Mazziotta et al., 2001), and the Brodmann 
template (Brodmann.nii) within MRIcron software 
(http://www.sph.sc.edu/comd/rorden/mricron/main.html). 
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3. Results 
3.1. Main motor effects on neural activation  
The main motor effects (i.e. regions activated by the motor task experimental condition 
across each drug condition) activated an extensive brain network (Table 2; Figure 1).  
The largest significant cluster of increased activation was centred in the right cerebellum ([x 
y z] = [22 -54 -28], F = 10.48, p < 0.001), with a smaller cluster centred in the left cerebellum 
([x y z] = [-34 -62 -30], F = 5.75, p < 0.001). 
Five further less extensive clusters of increased activation were seen during motor task 
performance. The first was centred in the left postcentral gyrus ([x y z] = [-34 -28 56], F = 
7.70, p < 0.001), extending into the left supramarginal gyrus. There were two clusters 
centred in the left central operculum ([x y z] = [-44 -2 10], F = 6.28, p < 0.001 and [x y z] = [-
58 -20 18], F = 5.30, p < 0.001), extending into the left thalamus and parietal operculum, 
respectively. There was a fourth cluster centred in the right inferior frontal operculum ([x y z] 
= [46 12 2], F = 5.48, p = 0.001). The final cluster was centred in the superior temporal gyrus 
([x y z] = [64 -32 16], F = 5.02, p = 0.004). There was also a trend-level significance for a 
cluster centred in the right caudate ([x y z] = [26 -10 30], F = 5.20, p = 0.099). 
[Table 2] 
[Figure 1] 
3.3 Treatment effects 
3.3.1 Main effect of treatment 
The repeated measures ANOVA revealed three clusters of activation where a significant 
main effect of treatment was observed (Table 3; Figure 2). 
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The first significant cluster was centred in the posterior orbital gyrus (anterior insula) ([x y z] 
= [-32 16 -18], F = 20.11, p = 0.002). The second cluster was centred in the inferior temporal 
gyrus ([x y z] = [-48 -58 -16], F = 15.38, p = 0.027), and the final cluster was centred in the 
postcentral gyrus ([x y z] = [-28 -30 56], F = 13.73, p = 0.037). 
[Figure 2] 
Figure 3 shows the parameter estimates for each drug session for regions displaying a 
significant main effect of drug treatment. 
[Figure 3] 
3.3.2 Haloperidol versus placebo 
Haloperidol led to increased activation in a number of regions compared with placebo, with 
five clusters of significant activation (see Table 2 for cluster coordinates and Figure 4 for 
activation patterns).  
A first cluster was centred in the left anterior insula ([x y z] = [-32 -16 -18], Z = 6.24, p < 
0.001), extending into the posterior orbital gyrus and the inferior orbital frontal gyrus. There 
were bilateral clusters centred in the inferior temporal gyrus, smaller on the right (L: [x y x] = 
[-48 -58 -16], F = 5.47, p = 0.002; R: [x y x] = [52 -42 -16], F = 4.50, p = 0.027). Further, 
there was a cluster in the left postcentral gyrus ([x y z] = [-28 -39 56], F = 5.21, p < 0.001), 
which extended into the bilateral precentral gyrus. The final cluster was centred in the left 
posterior cingulate gyrus ([x y z] = [-6 -48 16], F = 5.04, p = 0.023).  
There were no regions of lower activation during the motor task following haloperidol 
administration when compared with placebo. 
 [Figure 4] 
3.3.2 Haloperidol versus aripiprazole 
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Haloperidol induced greater activation than aripiprazole in two significant clusters. Cluster 
coordinates are listed in Table 2 and the activation patterns are illustrated in Figure 4.  
First, there was greater activation in the left posterior orbital gyrus ([x y z] = -36 24 -22], F = 
4.63, p = 0.045), extending into the left anterior insula. The second cluster was centred in 
the right postcentral gyrus ([x y z] = [34 -30 68], F = 4.59, p < 0.001).  
There were no regions of significantly lower activation during the motor task following 
haloperidol administration compared with aripiprazole.  
3.3.3 Aripiprazole versus placebo 
We found no differences in brain activation during the motor task when aripiprazole and 
placebo were compared directly.  
Figure 5 shows the parameter estimates for each drug session for additional regions 
identified in exploratory and hypothesis-led directional contrasts between drug sessions. 
[Figure 5] 
3.4 Region of interest analyses 
In the repeated-measures ANOVA, hypothesis-led analysis using small volume correction 
identified main effects of treatment in the a priori specified anatomical regions of interest at 
trend-level of significance. These were in the precentral gyrus ([x y z] = [-28 -30 56], T = 
13.73, Z = 3.87, P = 0.069) and post-central gyrus ([x y z] = [-28 -30 46], T = 13.35, Z = 3.82, 
P = 0.089), although they likely reflect a common activation spanning both regions. The 
analysis also identified a significant main effect in the putamen ([x y z] = [24 4 -6], T = 10.74, 
Z = 3.44, p < 0.088). 
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The post-hoc directional t-tests comparing treatments directly showed significantly greater 
task-related activation for haloperidol compared with placebo in the precentral gyrus ([x y z] 
= [-28 -30 56], T = 5.21, Z = 4.38, p < 0.001), the postcentral gyrus ([x y z] = [-26 -30 54], T = 
5.15, Z = 4.34, p = 0.011), and the putamen ([x y z] = [24 4 -6], T = 4.61, Z = 3.99, p = 
0.012). Furthermore, a trend-level effect was also observed in the supplementary motor area 
([x y z] = [2 -20 72], T = 4.17, Z = 3.68, p=0.057). Interestingly, haloperidol was also 
associated with a significant reduction in task-related BOLD activity in the caudate nucleus 
([x y z] = [8 18 10], T = 4.13, Z = 3.66, p = 0.036). 
When assessing the degree to which haloperidol modulated task-related regional brain 
recruitment relative to aripiprazole, we found evidence for significantly greater levels of 
activity in the postcentral gyrus ([x y z] = [34 -30 68], T = 4.59, Z = 3.98, p = 0.042), and at 
trend level in the precentral gyrus ([x y z] = [36 -28 68], T = 4.34, Z = 3.81, p = 0.011) in the 
haloperidol sessions. However, following correction for multiple comparisons, only the 
difference between haloperidol and placebo in the precentral gyrus remained significant. 
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4. Discussion  
This is the first study to examine the effects of aripiprazole on brain activation during a 
simple motor task in healthy individuals. Our main finding is that motor activation following 
aripiprazole did not differ from placebo. In contrast, following haloperidol there was an 
extensive increase in activation in frontal, temporal and insular regions, as well as in regions 
of the primary motor cortex, compared with both placebo and aripiprazole. These different 
effects are likely to be explained by the different pharmacological profiles of these two 
antipsychotics. While haloperidol is a selective dopamine D2 antagonist, aripiprazole is a D2 
partial agonist, acting on other receptors, including those of the serotoninergic system. 
Performance of the paced motor task was associated with significantly elevated BOLD signal 
in a distributed network including the contralateral sensorimotor cortices (postcentral and 
parietal operculum), the SMA, the ipsilateral cerebellum and subcortically the dorsal caudate 
nucleus, the putamen and thalamus. As described earlier, these regions form the basis of the 
cortico-striato-thalamocortical loop identified by Alexander et al. (1990). Similar patterns of 
activation are also consistent both with the findings of recent ALE meta-analyses of finger-
tapping tasks (Witt et al., 2008) and simple motor movements (Turesky et al. 2016), with these 
regions reflecting a core network underlying basic motor performance. Here, the SMA was 
linked to voluntary action and planning, while the basal ganglia and cerebellum are heavily 
implicated in both the initiation, control and timing of motor action and these aspects likely 
contribute to these two structures recruitment in this context. In both meta-analyses, task 
performance was also associated with increased activation of the inferior frontal operculum 
extending into the insula. This area has previously been implicated in externally paced motor 
performance, albeit visually cued (Witt et al., 2008). While perhaps not initially considered a 
motor area, the insula has extensive reciprocal connectivity with motor and sensory areas 
(Augustine 1996), and it is considered a motor association area linked to the upper body and 
hand (Chollet et al. 1991; Weiller et al. 1992). In patients with Parkinson’s disease, 
performance of externally-cued joystick movement was similarly associated with recruitment 
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of this network of brain regions. More importantly, impairment of dopamine signalling, due to 
the removal of L-dopa therapy, was associated with enhanced activation in the sensorimotor 
cortices, which accords with our findings (Maillet et al. 2012). 
There appeared to be no effect of either treatment on performance of the task, although 
aripiprazole did increase reaction times at a trend level. The lack of a clear effect may have 
been due to ceiling effects, with high levels of performance in healthy individuals meaning that 
there was little variability in inter-individual performance. However, given that haloperidol did 
affect neural activation but not behavioural performance, it is possible that higher activation in 
this condition reflected the need for motor regions to work harder to achieve comparable 
performance. Nonetheless, the absence of a significant behavioural effect gives confidence 
that the differences in neuronal recruitment indexed by the observed changes in BOLD 
contrast following haloperidol administration are not simply central representations of 
performance deficits.  
Examining our neuroimaging data, we report, for the first time, that aripiprazole does not alter 
brain activation during performance of a motor task. This is in contrast with other SGA, which 
have been reported to decrease activation of cortical motor regions in patient populations 
(Muller et al., 2002a,b). This might reflect differences between the mechanisms of action of 
aripiprazole and other SGAs, such as the D2 antagonism of many SGAs as opposed to the 
partial D2 agonism of aripiprazole. Furthermore, aripiprazole has a lower affinity for the 5-
HT2A than the D2 receptor, and partial affinity for 5-HT1A receptors. This profile may also 
explain why aripiprazole has been found in clinical trials to have a low risk of inducing 
extrapyramidal motor side effects (Fleischhacker, 2005).  
In contrast to aripiprazole, our hypothesis-led analyses revealed that haloperidol enhanced 
activation in several regions compared with both placebo and aripiprazole, including the 
putamen. Increased activation here may result from an autoreceptor response following D2 
blockade. Previous work by our group has also shown greater perfusion in the putamen 
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following challenge with haloperidol (Handley et al., 2013), which may reflect an increased 
need for energy supply. Conversely, caudate activation was lower following haloperidol than 
placebo, suggesting a smaller autoreceptor response (and similarly this region showed lower 
perfusion than the putamen). In addition, differences between the activation seen in these 
regions may reflect their involvement in motor function, which relies more on putamen 
activation, while the caudate underlies cognitive activities. Recent findings in rodents have 
also highlighted the complexity of the interaction between haloperidol and discrete neural 
populations in the striatum (Yael et al. 2013). Specifically, haloperidol reduces medium spiny 
neuron activity and increases the likelihood of oscillatory activity, while increasing the firing of 
tonically active neurons (TANs). Importantly, the impact of these effects seems dependent 
upon cortical input. Consequently, the observed differences may reflect various complex 
interacting factors.  
Our exploratory whole-brain analyses identified a main effect of drug in a contralateral network 
of brain regions, including the posterior and lateral aspect of the orbitofrontal cortex, the 
inferior temporal, and postcentral gyri. Post-hoc directional tests confirmed that activation was 
enhanced in the temporal lobe following haloperidol compared with placebo, but that no such 
effect of aripiprazole was evident. Neither was a difference in temporal activation seen when 
the FGA and SGA study arms were compared. This finding is consistent with the greater 
dopaminergic modulation of FGAs than SGAs, and with the fact that the temporal lobe is 
densely populated with dopamine receptors and may be an extrastriatal site of action for 
antipsychotic medications (Tuppurainen et al., 2009). The temporal lobe is consistently 
implicated in the pathophysiology of schizophrenia, and evidence suggests this activation may 
reflect a response to the auditory stimulation that provided the pacing in this task (Jones et al., 
2004). 
A task-related enhancement of the OFC and postcentral gyrus was evident on haloperidol 
compared with both placebo and, importantly, aripiprazole, suggesting that these regions were 
not even moderately modulated by aripiprazole. The orbitofrontal cortex contributes to the 
Corresponding author: Rhianna Goozee 
19 
 
limbic cortico-striato-thalamocortical circuit, which is linked to ventral striatal information 
processing (Alexander et al., 1990). Indeed, abnormalities of OFC have been related to the 
presence of both psychotic and cognitive symptoms in patients with schizophrenia (Waltz et 
al. 2007). Our finding of enhanced activation following haloperidol would be consistent with 
prior evidence that haloperidol, but not the SGA sertindole, increases metabolism in this area 
(Buchsbaum et al. 2009). This could be related to its therapeutic effects, as evidence from 
animal models suggests that antipsychotics reduce the impact of NMDA hypofunction and 
dopamine hyperfunction on OFC neurons, normalizing their function (Homayoun & 
Moghaddam 2008).  
As mentioned previously, haloperidol is a full dopamine antagonist, whereas aripiprazole is a 
partial agonist, with accompanying serotoninergic action. Therefore, the differences in 
activation we observed may be related to the partial agonism at D2 receptors of aripiprazole, 
or its serotoninergic modulation. Dopamine is primarily implicated in motor function, but further 
modulation after aripiprazole may occur indirectly via its serotoninergic action (Meltzer 2004), 
which has also been shown to play a role in motor function (Hasbroucq et al., 1997; Jacobs & 
Fornalt, 1997). Compared with haloperidol, there was lower activation following aripiprazole 
in several brain regions. Drugs that increase serotonin neurotransmission increase 
contralateral cortical motor activation, and so in the present case, 5HT2A receptor antagonism 
following aripiprazole may have mediated the lower activation observed (Loubinoux et al., 
2002). Furthermore, aripiprazole induced lower activation than haloperidol in regions of the 
prefrontal cortex (e.g. the inferior frontal gyrus), an area that is modulated by serotonin activity 
(Mann et al., 1996; Bowen et al., 1989). Nonetheless, aripiprazole did not alter activation in 
any of these areas when compared with placebo, suggesting that dopaminergic signalling is 
of primary importance in determining alterations from healthy activation following antipsychotic 
administration.  
To our knowledge, no other study has explored the effects of aripiprazole on neural 
activation associated with motor function in healthy controls, making comparison difficult. 
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Only one study explored the effect of haloperidol and, in contrast to us, found decreased  
activation in motor networks after this drug (Tost et al., 2006). This could be due to 
methodological differences, as our study benefited from a much larger sample and used a 
lower haloperidol dose than did Tost and colleagues. It is possible that in a smaller sample a 
pattern of increased activation could have not been detected. Also, participants in their study 
performed a more demanding task, using their non-dominant hand, with self-paced, 
repetitive finger to thumb coordination, and the direction regularly changed. This task, and 
the use of a greater dose of haloperidol, may mean that the dopamine antagonism elicited 
overrode any potential compensatory mechanism.  
Our participants completed the task with their right (dominant) hand and the effects we saw 
appeared to be lateralised. Increased activation during motor function following haloperidol 
compared with placebo was seen mainly in the contralateral (left) hemisphere. A review of 
motor cortex lateralisation in healthy individuals has reported that motor tasks elicit activation 
primarily in contralateral motor areas, which is consistent with our results (Mattay and 
Weinberger, 1999). Furthermore, our results suggest that haloperidol does not interfere with 
normal lateralised motor activation patterns. This is contrary to proposals presented 
elsewhere that reduced lateralisation of cognitive or motor activation in patients with 
schizophrenia is due to medication effects (Mattay et al., 1997; Walter et al., 2003; Bertolino 
et al., 2004). Indeed, studies investigating the effects of antipsychotic treatments in patients 
have suggested there may be lateralised effects on motor activation. For example, in one 
study reduced contralateral activation in the primary motor cortex was seen in unmedicated 
patients (Bertolino et al., 2004). However, after 8 weeks of treatment, there was increased 
lateralisation such that patients did not differ from healthy controls (Bertolino et al., 2004). 
Caution must also be taken when extrapolating data from healthy individuals to patient 
populations. In schizophrenia, dopamine signalling is disrupted, and the brain may respond 
differently to antipsychotic medications that modulate this neurotransmitter. Thus, while 
aripiprazole did not alter brain function in our healthy sample, this may not be true in 
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patients, who are starting from a different baseline brain state. Furthermore, patients receive 
long-term, multiple doses of antipsychotic medications, whereas studies in healthy 
individuals commonly use a single dose. These limitations highlight the need to integrate 
studies in healthy populations with clinical studies (particularly in antipsychotic-naïve 
patients) to explore the potential effects of different antipsychotic medications on motor 
function, and its relationship with symptomatic improvement. In addition, we did not record 
information on actual responses made by participants, particularly any made to the tone 
during the rest condition. This may be relevant to the interpretation of the contrast between 
experimental and rest conditions. In fact, if participants are responding during the rest 
blocks, this may reduce the differences seen. However, any response during rest would be 
likely to make the two conditions more similar rather than introducing more difference. 
Despite these limitations, investigating healthy controls is a major strength of our study. This 
approach allows the effects of antipsychotic drugs on brain function to be examined without 
the confounding influence of underlying disease pathophysiology. Comparing two different 
drugs and placebo within the same individuals, as we do in this within-subjects and 
counterbalanced design, gives greater confidence that changes in motor activation are due 
to the antipsychotic rather than between-group differences. Such a powerful, repeated 
measures analysis would not be easy to implement in patients with psychosis as changing 
medications in this way would have ethical implications.  
Motor function deficits are widely reported in schizophrenia and may underlie a number of 
other cognitive deficits associated with the disorder (Salthouse, 1996). Furthermore, 
abnormalities in motor function are observed in patients with schizophrenia who have never 
taken antipsychotic medications (Pappa & Dazzan, 2009). Antipsychotics exert modulatory 
effects on cognitive functions, including simple motor function, and antipsychotic generation 
plays a role in determining these effects. This study provides evidence for differential effects 
of FGA and SGA administration on neural activation associated with simple motor function in 
a healthy population without the complication of disease-related pathophysiology. Motor 
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deficits and other neurocognitive impairments have been associated with clinical and 
functional outcome in schizophrenia (Lepage et al., 2014). As such, they are a potentially 
suitable target for antipsychotic treatment, and a better understanding of the effects of 
antipsychotics on this domain is essential to improve the pharmacological management of 
schizophrenia.  
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Tables and figure legends 
Table 1: Motor task performance under each intervention  
Table 2: Neural correlates of significantly increased activation during the experimental 
condition of the motor task, and areas showing significant increases following haloperidol, 
compared with placebo and aripiprazole.  
Table 3: Motor function region of interest analysis after haloperidol compared with placebo, 
and after haloperidol compared with aripiprazole.  
Figure 1:1 Brain regions significantly activated during the performance of the motor task 
during the placebo session (pFWE < 0.05 on the basis of cluster extent). 
Figure 2: Brain regions where a significant main effect of treatment was evident in the 
repeated measures ANOVA (pFWE < 0.05 on the basis of cluster extent). 
Figure 3: Plots of parameter estimates for each drug session for regions displaying a 
significant main effect of drug treatment.  
Figure 4: Brain regions where Haloperidol significantly increased task-related activation 
compared to the Placebo (red) and Aripiprazole (Yellow) sessions (P(FWE) <0.05 on the 
basis of cluster extent). Common areas shown in orange. 
Figure 5: Plots of parameter estimates for each drug session for additional regions identified 
in exploratory and hypothesis-led directional contrasts between drug sessions. 
 
